Rivastigmine patches alone or combined with memantine compared with memantine alone in patients with moderate to severe Alzheimer's disease: Systematic review of the literature
PDF (Español)
HTML (Español)

Keywords

Alzheimer disease
holinesterase inhibitors
consumer product safety
memantine
review
treatment outcome (MeSH)

Abstract

Introduction: Alzheimer's disease (AD), an irreversible, progressive neurodegenerative condition, is the most common cause of dementia and generates a high economic burden. The aim of this study was to conduct a systematic review of the literature to determine the safety and efficacy of rivastigmine patch, alone or in combination with memantine, compared with memantine monotherapy for the treatment of moderate to severe AD.

Methods: A systematic search of the literature was conducted. Including randomized controlled trials of patients diagnosed with moderate to severe AD, evaluating outcomes of effectiveness and safety.

Results: The results of experimental studies comparing doses of rivastigmine patches indicate a possible difference in some of the outcomes of effectiveness such as performance in activities of daily living, instrumental activities, and overall functioning, in patients with moderate and severe AD, without significant difference in safety outcomes. A trend in favor of combination therapy in some of the outcomes, as change in MMSE score and instrumental daily activities, was observed.

Discussion: The available evidence supports the use of rivastigmine, and the association with memantine seems an appropriate therapeutic option in selected cases.

https://doi.org/10.22379/24224022118

PDF (Español)
HTML (Español)

References

Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Velting DM. A 24-week, open-label extension study to investigate the long-ter, safety, tolerability, adn efficacy of 13.3 mg/24 h rivastigmine patch in patients with severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2015;29(2):110-6.

Thies W, Bleiler L. 2013 Alzheimer's disease facts and figures. Alzheimer's Dement. 2013;9(2):208-45.

Alzheimer's, Association. 2010 Alzheimer's disease facts and figures. Alzheimer's Dement. 2010;6(2):158-94.

Prada SI, Takeuchi Y, Ariza Y. Costo monetario del tratamiento de la enfermedad de Alzheimer en Colombia. Acta Neurol Colomb. 2014;30(1):247-55.

Allegri RF, Arizaga RL, Bavec C V, Colli LP, Demey I, Golimstok Á, et al. Enfermedad de Alzheimer. Guía de práctica clínica. Neurol Arg. 2011;3(2):120-37.

Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112-7.

Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher dose rivastigmine patch (15 vs. 10 cm2) in Alzheimer's disease. Dement Geriatr Cogn Disord. 2012;33(5):341-53.

Ruiz de Sánchez C, Nariño D, Muñoz Cerón JF. Epidemiología y carga de la enfermedad de Alzheimer. Acta Neurol Colomb. 2010;26(Sup 3:1):87-94.

Súarez-Revelo X, Ochoa-Gomez JF, Tobón-Quintero CA, Duque-Grajales JE. Conectividad funcional en adultos mayores a partir de resonancia magnética funcional como un posible indicador para la enfermedad de Alzheimer. Acta Neurol Colomb. 2014;30:273-81.

Robert P, Ferris S, Gauthier S, Ihl R, Winblad B, Tennigkeit F. Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Alzheimers Res Ther. 2010;2(4):24.

Doraiswamy PM, Kaiser L, Bieber F, Garman RL. The Alzheimer's disease assessment scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer Dis Assoc Disord. 2001;15(4):174-83.

MacKenzie DM, Copp P, Shaw RJ, Goodwin GM. Brief cognitive screening of the elderly: a comparison of the Mini-Mental State Examination (MMSE), Abbreviated Mental Test (AMT) and Mental Status Questionnaire (MSQ). Psychol Med. 1996;26(2):427-30.

Rosselli D, Ardila A, Pradilla-Ardila G, Morillo L, Bautista L, Rey O, et al. El examen mental abreviado (Mini-Mental State Examination) como prueba de tamizaje para el diagnóstico de demencia: estudio poblacional colombiano. Rev Neurol. 2000;30(5):428-32.

Graham D, Cully J, Snow A, Massman P, Doody R. The Alzheimer's Disease Assessment Scale-Cognitive subscale: normative data for older adult controls. Alzheimer Dis Assoc Disord. 2004;18(4):236-40.

Sheehan B. Assesment scales in dementia. Ther Adv Neurol Disord. 2012;5(6):349-58.

Reisberg B. Global measures: utility in defining and measuring treatment response in dementia. Int Psychogeriatrics. 2007;19(3):421-56.

Busner J, Targum SD. The Clinical Global Impressions Scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28-37.

Medeiros K de, Robert P, Gauthier S, Stella F, Politis A, Leoutsakos J, et al. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychogeriatrics. 2010;22(6):984-94.

Peavy GM, Salmon D, Rice V, Galasko D, Samuel W, Taylor K, et al. Neuropsychological assessment of severely demented elderly: the severe cognitive impairment profile. Arch Neurol. 1996;53(4):367-72.

Ferris S, Ihl R, Robert P, Winblad B, Gatz G, Tennigkeit F, et al. Severe Impairment Battery Language scale: a language assessment tool for Alzheimer's disease patients. Alzheimer's Dement. 2009;5(5):375-9.

Shao Z, Janse E, Visser K, Meyer AS. What do verbal fluency tasks measure? Predictors of verbal fluency performance in older adults. Front Psychol. 2014;5:772-82.

Saxton J, Kastango KB, Hugonot-Diener L, Boller F, Verny M, Sarles CE, et al. Development of a short form of the Severe Impairment Battery. Am J Geriatr Psychiatry. 2005;13(11):999-1005.

Lock A, Nielsen H, Kragh-Sørensen P. Procedures in evaluating dementia - A study of conjoint application of two rating scales (SCAG and BCRS) and psychometric tests. Acta Psychiatr Scand. 1998;78(5):592-8.

Salthouse TA. What cognitive abilities are involved in trail-making performance? Intelligence. 2011;39(4):222-32.

Donaldson C, Atkinson A, Bond J, Wright K. QALYs and long-term care for elderly people in the UK: Scales for assesment of quality of life. Age Ageing. 1988;17(6):379-87.

Díaz M, Peña E, Mejía A, Flórez I. Manual para la elaboración de evaluaciones de efectividad, seguridad y validez diagnóstica de tecnologías en salud. Bogotá DC: Instituto de Evaluación Tecnológica en Salud - IETS; 2014.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-34.

Choi SH, Park KW, Na DL, Han HJ, Kim E-J, Shim YS, et al. Tolerability and efficacy of memantine add on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. Curr Med Res Opin. 2011;27(7):1375-83.

Farlow MR, Alva G, Meng X, Olin JT. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Curr Med Res Opin. 2010;26(2):263-9.

Nakamura Y, Imai Y, Shigeta M, Graf A, Shirahase T, Kim H, et al. A 24 week, randomized, double blind, placebo controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dement Geriatr Cogn Dis Extra. 2011;1(1):163-79.

Articus K, Baier M, Tracik F, Kühn F, Preuß UW, Kurz A, et al. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease. Int J Clin Pract. 2011;65(7):790-6.

Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Somogyi M. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia. CNS Neurosci Ther. 2013;19(10):745-52.

Grossberg GT, Manes F, Allegri RF, Gutiérrez-Robledo LM, Gloger S, Xie L, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): A multinational, randomized, double blind, placebo controlled trial in patients with moderate to severe alzheimer's disease taking cholinesterase inhibitors. CNS Drugs. 2013;27(6):469-78.

Grossberg GT, Farlow MR, Meng X, Velting DM. Evaluating high dose rivastigmine patch in severe Alzheimer's sisease?: Analyses with concomitant memantine usage as a factor. Curr Alzheimer Res. 2015;12(10):53-60.

Kulkantrakorn K, Tanyakitpisal P, Towanabut S, Dejthevaporn C, Rangseekajee P, Pongpakdee S, et al. Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand. Psychogeriatrics. 2013;13(1):1-8.

Safirstein B, Meng X, Olin JT. Rivastigmine and concomitant memantine in alzheimer's disease: Safety and tolerability. CNS Spectr. 2010;15(9):594-8.

Gareri P, Putignano D, Castagna A, Cotroneo AM, DePalo G, Fabbo A, et al. Retrospective study on the benefits of combined memantine and cholinesterase inhibitor treatment in aged patients affected with Alzheimer's disease: The MEMAGE Study. J Alzheimers Dis. 2014;41(2):633-40.

Micca JL, Galvin JE, Velting DM, Meng X. Efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on activities of daily living in severe Alzheimer's disease. SAGE Open Med. 2014;2(2050312114561569):1-7.

Seibert J, Tracik F, Articus K, Spittler S. Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer's disease in daily practice. Neuropsychiatr Dis Treat. 2012;8:141-7.

Birks JS, Evans JG. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2015;(4):1-197.

Molinuevo JL, Arranz FJ. Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer's disease. Expert Rev Neurother. 2012;12(1):31-7.

Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22(5):456-67.

Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract. 2009;63(5):799-805.

Mercier F, Lefèvre G, Huang H-LA, Schmidli H, Amzal B, Appel-Dingemanse S. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin. 2007;23(12):3199-204.

Adler G, Mueller B, Articus K. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions. Int J Clin Pract. 2014;68(4):465-70.

Spalletta G, Baldinetti F, Buccione I, Fadda L, Perri R, Scalmana S, et al. Cognition and behaviour are independent and heterogeneous dimensions in Alzheimer's disease. J Neurol. 2004;251(6):688-95.

Cano Gutiérrez CA, Matallana Eslava DL, Reyes Gavilán P, Montañés Ríos P. Cambios en las actividades instrumentales de la vida diaria en la enfermedad de Alzheimer. Acta Neurol Colomb 2010;26:Sup(3:1):112-21.

Schulz R, O'Brien A, Czaja S, Ory M, Norris R, Martire LM, et al. Dementia caregiver intervention research: in search of clinical significance. Gerontologist. 2002;42(5):589-602.

Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77(4):371-83.

Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22(3):209-21.

Cagnin A, Cester A, Costa B, Ermani M, Gabelli C, Gambina G. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease. Neurol Sci. 2014;36:457-63.

Dhillon S. Rivastigmine transdermal patch. Drugs. 2011;71(9):1209-31.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Downloads

Download data is not yet available.